Alzheimer’s Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?
International Journal of Molecular Sciences · 31.03.2024 · 25 (7) · 3892
DOI: 10.3390/ijms25073892 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 31.03.2024. Verfasst von Poul F Høilund-Carlsen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Odense University Hospital, 5000 Odense C, Denmark. Hauptthemen laut MEDLINE: Alzheimer Disease, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
The amyloid cascade hypothesis for Alzheimer’s disease is still alive, although heavily challenged. Effective anti-amyloid immunotherapy would confirm the hypothesis’ claim that the protein amyloid-beta is the cause of the disease. Two antibodies, aducanumab and lecanemab, have been approved by the U.S. Food and Drug Administration, while a third, donanemab, is under review. The main argument for the FDA approvals is a presumed therapy-induced removal of cerebral amyloid deposits. Lecanemab and donanemab are also thought to cause some statistical delay in the determination of cognitive decline. However, clinical efficacy that is less than with conventional treatment, selection of amyloid-positive trial patients with non-specific amyloid-PET imaging, and uncertain therapy-induced removal of cerebral amyloids in clinical trials cast doubt on this anti-Alzheimer’s antibody therapy and hence on the amyloid hypothesis, calling for a more thorough investigation of the negative impact of this type of therapy on the brain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Odense University Hospital, 5000 Odense C, Denmark.
- Research Unit of Clinical Physiology and Nuclear Medicine, Department of Clinical Research, University of Southern Denmark, 5230 Odense M, Denmark.
- Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
- Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
- Gene Delivery Technology Core, Massachusetts General Hospital, Boston, MA 02114, USA.
- Department of Neuroscience, Developmental and Regenerative Biology and Genetics of Neurodegeneration, University of Texas at San Antonio, San Antonio, TX 78249, USA.
ORCID-Profile: Poul F Høilund-Carlsen, Abass Alavi, Rudolph J Castellani, Rachael L Neve, George Perry, Mona-Elisabeth Revheim, Jorge R Barrio
Zitieren
APA
Høilund-Carlsen, P. F., Alavi, A., Castellani, R. J., Neve, R. L., Perry, G., Revheim, M. E., & Barrio, J. R. (2024). Alzheimer’s Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?. International Journal of Molecular Sciences, 25(7), 3892. https://doi.org/10.3390/ijms25073892
Vancouver
Høilund-Carlsen PF, Alavi A, Castellani RJ, Neve RL, Perry G, Revheim ME, et al. Alzheimer’s Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?. International Journal of Molecular Sciences. 2024;25(7):3892. doi:10.3390/ijms25073892
BibTeX
@article{HilundCarlsen2024,
author = {Høilund-Carlsen, Poul F and Alavi, Abass and Castellani, Rudolph J and Neve, Rachael L and Perry, George and Revheim, Mona-Elisabeth and Barrio, Jorge R},
title = {Alzheimer’s Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {7},
pages = {3892},
doi = {10.3390/ijms25073892}
}
EUVIMED